Trial · NCT00605865
Outcomes16
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants of Treatment Related Adverse Events (TRAEs) | Baseline up to 16 weeks | Safety analysis population included all enrolled participants who had received at least 1 confirmed administration of Sertraline. | participants | NUMBER |
| PRIMARY | Number of Treatment Related Adverse Events (TRAEs) Not Expected From Japanese Package Insert | Baseline up to 16 weeks | The safety analysis population consists of the cases that satisfy the participant's conditions and in whom administration of Sertraline was confirmed. | events | NUMBER |
| SECONDARY | Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Complications | Baseline up to 16 weeks | The safety analysis population consists of the cases that satisfy the participant's conditions and in whom administration of Sertraline was confirmed. | participants | NUMBER |
| SECONDARY | Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Concomitant Drug | Baseline up to 16 weeks | The safety analysis population consists of the cases that satisfy the participant's conditions and in whom administration of Sertraline was confirmed. | participants | NUMBER |
| SECONDARY | Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Renal Dysfunction | Baseline up to 16 weeks | The safety analysis population consists of the cases that satisfy the participant's conditions and in whom administration of Sertraline was confirmed. | participants | NUMBER |
| SECONDARY | Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Past Medical History of Other Illness | Baseline up to 16 weeks | The safety analysis population consists of the cases that satisfy the participant's conditions and in whom administration of Sertraline was confirmed. | participants | NUMBER |
| SECONDARY | Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Average Daily Dose | Baseline up to 16 weeks | The safety analysis population consists of the cases that satisfy the participant's conditions and in whom administration of Sertraline was confirmed. | participants | NUMBER |
| SECONDARY | Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Suicidal Ideation (Including Suicide Attempt) | Baseline up to 16 weeks | The safety analysis population consists of the cases that satisfy the participant's conditions and in whom administration of Sertraline was confirmed. | participants | NUMBER |
| SECONDARY | Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: 15 Years and Higher of Age or Not | Baseline up to 16 weeks | The safety analysis population consists of the cases that satisfy the participant's conditions and in whom administration of Sertraline was confirmed. | participants | NUMBER |
| SECONDARY | Factors Considered to Affect the Efficacy of Sertraline: Target Disease Severity | Baseline up to 16 weeks | The efficacy analysis population consists of the evaluable cases in accordance with the analysis plan (cases judged to have been evaluated appropriately). | participants | NUMBER |
| SECONDARY | Factors Considered to Affect the Efficacy of Sertraline: History of Treatment Prior to Administration of Sertraline Hydrochloride | Baseline up to 16 weeks | The efficacy analysis population consists of the evaluable cases in accordance with the analysis plan (cases judged to have been evaluated appropriately). | participants | NUMBER |
| SECONDARY | Factors Considered to Affect the Efficacy of Sertraline: Outpatient/Inpatient | Baseline up to 16 weeks | The efficacy analysis population consists of the evaluable cases in accordance with the analysis plan (cases judged to have been evaluated appropriately). | participants | NUMBER |
| SECONDARY | Factors Considered to Affect the Efficacy of Sertraline: Complication ;Complications is the Patient's Current Experiences With Illnesses, Operations, Injuries and Treatments. | Baseline up to 16 weeks | The efficacy analysis population consists of the evaluable cases in accordance with the analysis plan (cases judged to have been evaluated appropriately). | participants | NUMBER |
| SECONDARY | Factors Considered to Affect the Efficacy of Sertraline: 15 Years and Higher of Age or Not | Baseline up to 16 weeks | The efficacy analysis population consists of the evaluable cases in accordance with the analysis plan (cases judged to have been evaluated appropriately). | participants | NUMBER |
| SECONDARY | Factors Considered to Affect the Efficacy of Sertraline: Age | Baseline up to 16 weeks | The efficacy analysis population consists of the evaluable cases in accordance with the analysis plan (cases judged to have been evaluated appropriately). | participants | NUMBER |
| SECONDARY | Factors Considered to Affect the Efficacy of Sertraline: Suicidal Ideation (Including Suicide Attempt) | Baseline up to 16 weeks | The efficacy analysis population consists of the evaluable cases in accordance with the analysis plan (cases judged to have been evaluated appropriately). | participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00605865/outcomes